00000000cam 2200000zi 4500
0019.951364
003CaOODSP
00520260901132434
006m     o  d f      
007cr cn|||||||||
008250526e20260204onc     ob   f000 0 eng d
020 |a9780660774138
040 |aCaOODSP|beng|erda|cCaOODSP
043 |an-cn---
0861 |aH139-90/2025E-PDF
24500|aGUI-0036 : |bannex 13 to the Good manufacturing practices guide - drugs used in clinical trials.
24617|aGUI-0036 : |bannex 13 to the GMP guide : drugs used in clinical trials, v3
264 1|aOttawa, ON : |bHealth Canada = Santé Canada, |cFebruary 4, 2026.
264 4|c©2024
300 |a1 online resource (31 pages)
336 |atext|btxt|2rdacontent
337 |acomputer|bc|2rdamedia
338 |aonline resource|bcr|2rdacarrier
500 |aIssued also in French under title: GUI-0036 : annex 13 aux Lignes directrices sur les bonnes pratiques de fabrication des médicaments utilisés dans les essais cliniques.
500 |aTitle from cover.
500 |a" Pub.: 250069"--Page [2].
504 |aIncludes bibliographical references (page 23).
520 |a"This guide is an annex to the Canadian Good manufacturing practices guidelines (GUI-0001). It applies to manufacturing, handling and storing of clinical trial drugs intended for use in clinical trials. Good manufacturing practices (GMP) are internationally recognized standards that apply to drug manufacturing. They ensure drug quality and safety. Drugs intended for use in clinical trials in Canada are regulated under Part C, Division 5 of the Food and Drug Regulations (regulations). Under section C.05.010(j), sponsors must ensure that drugs for use in clinical trials are manufactured, handled and stored in accordance with the applicable good manufacturing practices requirements referred to in Divisions 2 to 4. Exceptions are those requirements referred to in sections C.02.019, C.02.025 and C.02.026. Sponsors of clinical trials must also ensure that imported drugs are fabricated and packaged/labelled in accordance with these requirements. The relevant sections of the regulations are noted throughout. …"--Purpose, page 4.
650 0|aPharmaceutical industry|zCanada|xQuality control.
650 0|aDrugs|xSafety regulations|zCanada.
650 0|aDrugs|xStandards|zCanada.
650 0|aDrugs|xTesting.
7101 |aCanada. |bHealth Canada, |eissuing body.
77508|tGUI-0036 : |w(CaOODSP)9.951365
85640|qPDF|s318 KB|uhttps://publications.gc.ca/collections/collection_2026/sc-hc/H139-90-2025-eng.pdf
8564 |qHTML|sN/A|uhttps://www.canada.ca/en/health-canada/services/drugs-health-products/compliance-enforcement/good-manufacturing-practices/guidance-documents/annex-13-guide-drugs-clinical-trials-0036.html
986 |a250069